Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Deutsche Diabetes-Forschungsgesellschaft E V is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by a distinct examiner and 1 distinct art unit. Prosecution activity is currently limited to this point of contact, indicating a highly specific focus for the institution's current patent efforts.
MARTIN, KEVIN STEPHEN is the busiest examiner for the portfolio, overseeing the busiest examiner pending office action. This application represents the institution's current active pipeline in the biotech sector. The concentration of the portfolio under a single examiner allows for a direct and consistent dialogue during the prosecution of the technology.
Practitioners should note that the alignment of the pending matter within the specified technology area ensures that the examination is conducted by a specialist in biotechnology and pharmaceuticals. The focus on a single examiner and art unit provides a streamlined prosecution environment. This structure minimizes the complexity often associated with managing multiple examiner relationships across different technical units at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.2% | +23.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698701 | COMPOUND FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND RELATED DISEASES | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698701 | COMPOUND FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND RELATED DISEASES | MARTIN, KEVIN STEPHEN | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial